This article is more than 5 years old. Information may no longer be current.

Tissue plasminogen activator resolves submacular hemorrhage

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — A tissue plasminogen activator and pneumatic displacement of submacular hemorrhage offered nearly a 90% success rate for patients in a poster presented at the American Society of Retina Specialists meeting.

Colin S. Tan, MBBS, MMed (Ophth), FRCSEd (Ophth) , and colleagues presented the findings of 63 consecutive patients with submacular hemorrhage treated with tissue plasminogen activator (tPA) at a single Singapore institute. Patients received an intravitreal injection of 0.05 mL tPA, followed by 0.3 mL perfluoropropane (C3F8) and strict positioning afterward.

According to the study data, 89.3% of patients had treatment success and 66.1% of patients achieved clinically evident blood displacement. Blood dispersion was seen in 23.2% of patients. Treatment failure, which was described as having neither displacement nor dispersion of the blood, was noted in 10.7% of patients.

Treatment success led to better visual outcomes compared with those with treatment failures. Patients with displaced hemorrhages had the best visual outcomes at final follow-up, compared with those had only hemorrhage dispersion or treatment failure. – by Robert Linnehan

Reference:

Tan CS, et al. Pneumatic displacement of submacular hemorrhage using tissue plasminogen activator. Presented at: American Society of Retina Specialists 35th Annual Meeting, Aug. 11-15, 2017; Boston.

Disclosure: Tan reports he receives travel support from Bayer, Heidelberg Engineering and Novartis. He reports he receives research support from the National Healthcare Group Clinician Scientist Career Scheme Grant.